Duchenne gene therapy setback, Alzheimer’s drug endorsement

On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us to explain what it means to be a reporter who writes about the commercial determinants of health. Hint: Florko’s most recent stories focused on weed, vapes and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism.

Also this week, co-hosts Adam Feuerstein and Allison DeAngelis chat about Pfizer’s Duchenne gene therapy setback, the likely approval of a new treatment for Alzheimer’s disease, and Bob Langer’s most recent startup.

To learn more about Florko’s coverage of vapes, look here; his story on buying raw milk — and why you shouldn’t do it, too — can be found here. To read about the failure of Pfizer’s gene therapy study, go here, and a recap of the FDA advisory panel that reviewed Eli Lilly’s Alzheimer’s drug can be found here. Bob Langer’s new startup details are here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.